Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.29 -1.74%

-$0.25 today

Market cap
$629.58M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.65M

Average 1.02M

Income Statement

Follow revenue through to earnings.

Revenue

$10.00M

FY 2025 · Annual

-5.6% YoY

Operating Income

-$157.67M

FY 2025 · Annual

Net Income

-$113.63M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.64M8.61M8.08M10.59M10M
Cost of Revenue26.24M841K1.96M2.06M2.03M
Gross Profit(22.6M)7.77M6.13M8.53M7.97M
Gross Margin-621.4%90.2%75.8%80.5%79.7%
Research & Development26.24M53.44M54.92M68.39M125.9M
Selling, General & Admin10.33M22.26M26.14M41.05M41.77M
Operating Expenses10.33M74.86M79.11M107.38M165.64M
Depreciation & Amortization113K841K1.96M2.06M2.03M
EBITDA(32.56M)(62.22M)(56.34M)(66.93M)(111.6M)
EBITDA Margin-895.2%-722.5%-697.0%-632.2%-1116.0%
Operating Income(32.93M)(67.09M)(72.98M)(98.85M)(157.67M)
Operating Margin-905.4%-779.0%-902.9%-933.6%-1576.7%
Interest Income257K4.03M14.69M29.85M44.04M
Interest Expense00000
Other Income / Expenses257K4.03M14.69M29.85M44.04M
Income Before Tax(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Pre-Tax Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
Income Tax Expense00000
Net Income(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Net Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
EPS (Basic)(0.79)(1.52)(1.32)(1.28)(1.83)
EPS (Diluted)(0.79)(1.52)(1.32)(1.28)(1.83)
Weighted Avg Shares41.24M41.47M44.02M53.75M61.97M
Weighted Avg Shares (Diluted)41.24M41.47M44.02M53.75M61.97M

JANX Earnings Waterfall · TTM

NASDAQ:JANX · Revenue to Net Income

Key Ratios

EPS$-1.84
Gross Margin42.2%
Net Margin-325.3%
P/E Ratio-10.4
P/S Ratio123.4

Analysis

$21.6M of revenue converted into -$114.5M of net income for the selected period. Gross margin is 42.2% and net margin is -325.3%, showing how much revenue survives after costs and taxes. EPS is $-1.84, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
SC 13G/ASC 13G/A filingAug 14, 2026
SC 13G/ASC 13G/A filingAug 13, 2026

How much revenue does JANX generate?

Janux Therapeutics, Inc. (JANX) reported $10.00M of revenue in fiscal 2025.

Is JANX profitable?

Janux Therapeutics, Inc. (JANX) reported -$113.63M of net income, with a net margin of -1136.3%.